HARP - Harpoon Therapeutics to Present Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager HPN328 at ESMO Congress 2023 | Benzinga
SOUTH SAN FRANCISCO, Calif., Oct. 09, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ:HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today announced that it will present interim monotherapy data from its Phase 1/2 clinical trial evaluating HPN328 in small cell lung cancer (SCLC) and other neuroendocrine neoplasms (NEN) in a poster presentation at the European Society of Medical Oncology Congress (ESMO) 2023 taking place in Madrid, Spain from October 20-24, 2023. HPN328 targets delta-like ligand 3 (DLL3) and is derived from Harpoon's proprietary Tri-specific T cell Activating Construct (TriTAC®) platform designed to recruit a patient's own immune cells to kill tumor cells.
"We are excited to present data from over 70 patients with multiple tumor types in HPN328 monotherapy cohorts, with an emphasis on our ongoing 1 mg priming cohorts with target doses up to 24 mg. Full enrollment of these 1 mg priming dose cohorts will be the basis for selecting our recommended Phase 2 dose(s) by the end of this year. In our poster, we will share tolerability data from all enrolled patients and preliminary response data in patients at doses above the efficacy threshold of 1.215 mg," said Luke Walker, M.D., Chief Medical Officer for Harpoon Therapeutics. "In addition to nearing completion of monotherapy dose optimization, we have recently initiated enrollment in our combination cohorts evaluating HPN328 plus atezolizumab to enable future development in early lines of therapy."
Details of the ESMO poster presentation are as follows:
Abstract Title: Interim Results from a Phase ...